A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis

NCT03432533 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

283

Enrollment

INDUSTRY

Sponsor class

Conditions

Post-Menopausal Osteoporosis

Interventions

DRUG: romosozumab HCP administration with PFS
DEVICE: romosozumab self-administration with AI/Pen

Sponsor

Amgen